In today's Just The Facts..
Perseus Mining has lodged a binding offer to acquire all remaining Predictive Discovery shares at a 24.5% premium. The deal strengthens its African gold portfolio, with the Bankan Project set to become a major new growth asset.
Biotech company Noxopharm has hit a key milestone, completing the first multi-dose cohort in its HERACLES trial with no safety issues. The lupus treatment SOF-SKN has been deemed safe, clearing the way for high-dose testing as the program now moves into its final stage.
Amplia Therapeutics has secured a major US patent for its FAK inhibitor narmafotinib, extending protection to at least 2040. The company says the grant strengthens its global IP portfolio as clinical development progresses.
#ASXNews #MiningStocks #GoldMining #PerseusMining #BiotechNews #ClinicalTrials #Noxopharm #LupusResearch #DrugDevelopment